Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo

Conclusion: Exacerbations on mepolizumab have less severe symptoms and tend to be less eosinophilic.Our data suggests an impaired symptomatic response to OCS for patients treated with mepolizumab compared to placebo. Further work is required to determine if different treatment approach is needed.

Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Shrimanker, R., Hargaden, B., Bradding, P., Wardlaw, A., Brightling, C., Green, R., Bafadhel, M., Pavord, I., Haldar, P., Heaney, L. Tags: Airway Pharmacology and Treatment Source Type: research